US Patent 7931903 Internalizing anti-CD74 antibodies and methods of use
Patent 7931903 was granted and assigned to IMMUNOMEDICS, INC. on April, 2011 by the United States Patent and Trademark Office.
All edits
Edits on 27 Nov, 2023
Golden AI
Edits made to:
Article (+487 characters)
Article
Patent abstract
The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.
Edits on 19 Sep, 2023
Golden AI
Edits made to:
Infobox (+3 properties)
Infobox
Patent Inventor Names
David M. Goldenberg0
Hans J. Hansen0
Zhengxing Qu0
Edits on 23 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 22 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07931903 Internalizing anti-CD74 antibodies and methods of use US Patent 7931903 Internalizing anti-CD74 antibodies and methods of use
Infobox
Patent Number
07931903
Patent Number
7931903
Edits on 19 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 7 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07931903 Internalizing anti-CD74 antibodies and methods of use
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07931903
Date of patent
April 26, 2011
Patent application number
12794823
Date Filed
June 7, 2010
Patent primary examiner
Find more entities like US Patent 7931903 Internalizing anti-CD74 antibodies and methods of use
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
